In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cathy Kelly

Senior Writer

Washington, DC

Cathy has covered prescription drug reimbursement issues for nearly 20 years, starting with the implementation of the Medicare Part D program. She has written extensively about developments in all the major US insurance sectors -- Medicare (Parts D and B), Medicaid and the employer-sponsored market. She has closely followed the increasing influence of pharmacy benefit managers and their use of formulary negotiations and rebates to control pricing. Cathy also has covered the implementation of frameworks for assessing drug value by medical professional organizations and the Institute for Clinical and Economic Review and is watching with interest as the government develops new policies aimed at lowering drug pricing.

For more than three decades, she has worked as a health care reporter and editor while raising three daughters. Cathy lives in Bethesda, MD with her husband Sean.

Latest From Cathy Kelly

Accelerated Approval Price Trends Show Sponsors Can ‘Lose But Not Win’ From Confirmatory Trials

Study drills down into the lack of economic incentives for conducting confirmatory studies to inform policies that could remedy to the situation.

Pricing Debate Review Pathway

Medicare Part D Price Inflation Rebates Won’t Mean As Much In Inflationary Times

Fewer rebate penalties than lawmakers expected may be assessed in the coming year because of the current high rate of general inflation.

Pricing Strategies Reimbursement

Manufacturer Donations To Copay Charities: Profitability Underscores Kickback Concerns – Study

Department of Justice anti-kickback expert seeks to quantify the potential for manufacturers to benefit from donations to independent copay assistances organizations.

Reimbursement Compliance

Medicare Part B And Accelerated Approvals: MedPAC Mulls Use Of CED Versus Payment Caps

Medicare advisory panel discusses ongoing issues around launch prices that were not addressed by the government price controls targeting older drugs enacted as part of the Inflation Reduction Act.

Policy Reimbursement

Medicare Part D Redesign: New Discounts Will Not Apply To Drugs With ‘Negotiated’ Prices

However, Part D drugs subject to government price setting under the Inflation Reduction Act will still face pharmacy benefit manager demands for additional rebates in return for preferential formulary status.

Pricing Debate Medicare

US House Republicans Launch Oversight Of Medicare Price ‘Negotiation’ Program

Offering a glimpse of what to expect if the GOP wins the House in the midterm elections, Reps. McMorris Rodgers and Brady urge transparency from HHS, ask lots of questions, and request monthly briefings on plans for implementation.

Pricing Debate Reimbursement
See All